Influvac® Tetra

Influvac® Tetra is an inactivated (surface antigen), quadrivalent influenza vaccine indicated for the prophylaxis of influenza, especially in those who run an increased risk of associated complications.

The composition of Influvac® Tetra complies with the WHO recommendations on the composition of influenza vaccines.1

Influvac® Tetra is indicated in adults and children from 3 years of age2.

What are the advantages of Influvac® Tetra?1

  • Influvac® Tetra provides active immunisation against 4 influenza virus strains. The constituents of Influvac® for the 2019/2010 season, as recommended by the World Health Organization, are as follows:
    • - an A/Brisbane/02/2018 (H1N1)pdm09-like virus;
    • - an A/Kansas/14/2017 (H3N2)-like virus;
    • -a B/Colorado/06/2017-like virus B/Victoria/2/87 lineage); and
    • -a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage)3.
  • Influvac® Tetra can be used in all stages of pregnancy and during breastfeeding.1
  • Influvac® Tetra is available in pre-filled, single-dose syringe (Single packs: syringes with needles. Packs of ten: Syringes can be ordered with/without needle).1
  • The safety profile of Influvac® Tetra builds on the well established safety profile of the trivalent vaccine, Influvac®.1

Influvac® Tetra with 4 influenza virus strains potentially offers a wider protection in case of vaccine strain mismatch.1,4

Since 1985, 2 antigenically distinct lineages of influenza B viruses (Victoria and Yamagata) have been co-circulating globally.5

Trivalent influenza vaccines contain only one B-strain; therefore, mismatch can occur between the recommended lineage for TIV and the circulating B-strain.4

Vaccine mismatch for circulating B strain was noted in 5 of the 10 previous influenza seasons (2001–2002 through 2010–2011).4

In the 2017-2018 season (till week 10/2018) in Europe, more influenza type B (66%) than type A (34%) viruses were detected.5

Siliconised needle designed
for injection comfort

The 0.25ml dose for children
<36 months of age is clearly marked

16mm needle length

Pre-filled to deliver the
exact 0.5ml dose

References

  • 1. Mylan. Influvac sub-unit, Imuvac and Influenza Vaccine / Influvac Tetra and Influenza Vaccine Tetra. Combined Prescribing Information 06JUN2018.
  • 2. Influvac® Tetra Patient Leaflet. Available at: https://www.medicines.org.uk/emc/product/9381/pil .Last accessed April 2019.
  • 3. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season. Available at: https://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/ .Last accessed April 2019.
  • 4. van de Witte SV, Nauta J, Giezeman-Smits KM, et al. Trivalent inactivated subunit influenza vaccine Influvac®: 30-year experience of safety and immunogenicity. Trials in Vaccinology. 2012;1:42-48.
  • 5. van de Witte S, Nauta J, Montomoli E, Weckx J. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses. Vaccine 2018;36(40):6030–6038.

The website you are trying to access is designed for healthcare professionals, the content is not designed for the general public.

Are you a healthcare professional?

YES
NO